Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PNT6555
- Development stage
- Phase 1
- Lead developer
- POINT Biopharma
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PNT6555 is a radioligand therapeutic agent designed to target fibroblast activation protein (FAP)-expressing tumors. It consists of a DOTA chelator linked to a FAP-targeting moiety (Bz-D-Ala-boroPro) and is labeled with the beta-emitting radioisotope lutetium-177. As part of the FAP inhibitor (FAPi) family, it delivers targeted beta radiation to tumor sites, aiming for high specificity and minimal off-target effects. Developed under the PNT2004 program, it is paired with its diagnostic counterpart 68Ga-PNT6555 for PET imaging, enabling theranostic approaches in oncology. Preclinical studies demonstrated potent antitumor activity and favorable safety profiles; clinical development has reached Phase I trials in multiple solid tumors characterized by FAP overexpression[1][3][4][6].
- Other names
- Lutetium-177 PNT6555Lutetium177 PNT6555Lutetium 177 PNT6555
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on PNT6555.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PNT6555.